Avandia's EU Judgment Day Postponed, But GSK Gets Some Good News From CHMP
This article was originally published in The Pink Sheet Daily
Executive Summary
New fondaparinux indication cleared as European advisory panel says it take two more months to review of Avandia's cardiovascular risks.